Multiple Sclerosis, Relapsing-Remitting
The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)
Drugs by status
Approved for this indication (6)
Phase 4 trials (31)
- fingolimod
- cladribine
- vitamin d3
- methylprednisolone
- corticotropin
- cetirizine
- citalopram
- prednisone
- ibuprofen
- dimethyl fumarate
- aciclovir
- naltrexone
- simethicone
- fluoxetine
- ofatumumab
- peanut
- acetaminophen
- donepezil
- acetylsalicylic acid
- alemtuzumab
- natalizumab
- vitamin k
- glatiramer acetate
- vitamin a
- venlafaxine
- esomeprazole
- loperamide
- interferon beta-1b
- peginterferon beta-1a
- ranitidine
- +1 more
Phase 3 trials (33)
- simvastatin
- 23-valent pneumococcal polysaccharide vaccine
- dalfampridine
- dirucotide
- fexofenadine
- warfarin
- Filgrastim
- keyhole limpet hemocyanin
- laquinimod
- pravastatin
- caffeine
- interferon alfa-1b
- immune globulin (human)
- ozanimod
- Vidofludimus
- cyclophosphamide
- Anti-thymocyte Globulin (Rabbit)
- multi-valent pneumococcal conjugate vaccine
- inactivated influenza vaccine
- mesna
- autologous mesenchymal stem cells
- midazolam
- rituximab
- acellular pertussis vaccine (including diptheria and tetanus toxoids)
- sodium chloride
- dextromethorphan
- omeprazole
- omega-3 fatty acids
- metenkefalin
- diroximel
- +3 more
Phase 2 trials (63)
- melatonin
- Flupirtine
- secukinumab
- bht-3009
- temsirolimus
- lamotrigine
- clofazimine
- gnbac1
- gsk239512
- aldesleukin
- hookworm larvae
- albumin (Human)
- insulin human
- ifenprodil
- mk0812
- nt-ko-003
- atorvastatin
- pleneva
- plovamer
- progestin
- carmustine
- Telitacicept
- rifabutin
- vatelizumab
- firategrast
- abatacept
- t131
- tabalumab
- testosterone
- tovaxin
- +33 more
Phase 1 trials (21)
- atx-ms-1467
- autologous vitd3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides
- methylphenidate
- gsk2018682
- gsk2618960
- guanabenz
- helminth ova
- ixazomib
- Olesoxime
- ozanezumab
- rhigm22
- rtl1000
- human fecal microbiota
- budesonide
- pioglitazone
- liothyronine
- opicinumab
- crotalidae antivenin polyvalent (equine)
- ank-700
- tolerogenic fibroblasts
- cd20/bcma-directed car-t cells
Organizations
Organization Involved with Phase 4 Indications (41)
- Merck Serono
- Elan Pharmaceuticals
- Genentech
- Merck KGaA
- Genzyme
- Pfizer
- Sanofi
- Biogen
- Novartis
- Bayer
- Mallinckrodt
- Neurognostics
- Teva
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- Cedars-Sinai Medical Center
- Cornerstone Health Care, PA
- Johns Hopkins University
- Medical College of Wisconsin
- University of New Mexico
- University of Rochester
- University of Chicago
- Ospedale Regionale di Lugano
- Ospedale Civico, Lugano
- University of Haifa
- University of Munster
- Free University of Amsterdam
- Adolphe Rothschild Ophtalmologic Foundation
- Amphia Hospital Breda, the Netherlands
- Government of Mexico
- University of Maribor
- +11 more
Organization Involved with Phase 3 Indications (63)
- AbbVie
- Serono
- Eli Lilly
- Ipsen
- Alkermes
- Amersham
- Biocad
- Mapi Pharma Ltd.
- Pronova BioPharma
- Byondis
- BioMS Technology Corp.
- National Institute of Neurological Disorders and Stroke (NINDS)
- Region Syddanmark
- Aarhus University
- University of Pennsylvania
- Alabama Neurology Associates, PC
- Central Jutland Regional Hospital
- Danderyds Hospital
- University of Washington
- Kocaeli University
- Northwestern University
- Norwegian University of Science and Technology
- Oregon Health and Science University
- Providence Health & Services
- Stanford University
- University Hospital of North Norway
- University of Oslo
- University of Southern Denmark
- University of Tehran
- University of Bergen
- +33 more
Organization Involved with Phase 2 Indications (86)
- GeNeuro
- Actelion
- Bristol-Myers Squibb
- Galapagos NV
- Servier
- Advancell - Advanced In Vitro Cell Technologies, S.A.
- Merck
- BTG
- Grifols
- Wyeth
- Bayhill Therapeutics
- Central Texas Neurology Consultants
- GlaxoSmithKline
- ImCyse
- InteKrin Therapeutics, Inc.
- Neurotec Pharma
- Novo Cellular Medicine Institute LLP
- RemeGen
- Revalesio Corporation
- Genesis Limited
- TG Therapeutics, Inc.
- German Research Foundation
- National Institutes of Health (NIH)
- National Center for Complementary and Integrative Health (NCCIH)
- National Center of Neurology and Psychiatry, Japan
- National Institute of Allergy and Infectious Diseases (NIAID)
- Maastricht University
- Banc de Sang i Teixits
- Baylor University
- University of London
- +56 more
Organization Involved with Phase 1 Indications (32)
- Acorda Therapeutics
- Takeda
- Artielle ImmunoTherapeutics
- BioPartners GmbH
- Apitope
- Repligen Corporation
- Case Western Reserve University
- Indiana University
- University of Lausanne
- University of Maryland
- University of Bonn
- Assiut University
- Centre for Probe Development and Commercialization
- Tel Aviv University
- Covance
- SGS Life Sciences
- Quotient
- Pharmaceutical Research Associates, Inc. (PRA)
- University of Reims
- Clinica Universidad de Navarra
- University of Wisconsin
- University of Illinois at Chicago
- Aix-University of Marseille
- General Electric
- BfARM, Bonn
- Deutsches Zentrum für Neurodegenerative Erkrankungen e. V.
- ClinStar, LLC
- Aptiv Solutions
- STRAGEN
- EvergreenHealth
- +2 more
Organization Involved with Other Experimental Indications (3)